These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 22145610)

  • 1. Population pharmacokinetics of ABT-594 in subjects with diabetic peripheral neuropathic pain.
    Dutta S; Awni W
    J Clin Pharm Ther; 2012 Aug; 37(4):475-80. PubMed ID: 22145610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population analyses of efficacy and safety of ABT-594 in subjects with diabetic peripheral neuropathic pain.
    Dutta S; Hosmane BS; Awni WM
    AAPS J; 2012 Jun; 14(2):168-75. PubMed ID: 22328206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain.
    Rowbotham MC; Duan RW; Thomas J; Nothaft W; Backonja MM
    Pain; 2009 Dec; 146(3):245-252. PubMed ID: 19632048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
    Zhu CZ; Chin CL; Rustay NR; Zhong C; Mikusa J; Chandran P; Salyers A; Gomez E; Simler G; Lewis LG; Gauvin D; Baker S; Pai M; Tovcimak A; Brown J; Komater V; Fox GB; Decker MW; Jacobson PB; Gopalakrishnan M; Lee CH; Honore P
    Biochem Pharmacol; 2011 Oct; 82(8):967-76. PubMed ID: 21620806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain.
    Yuen E; Gueorguieva I; Bueno-Burgos L; Iyengar S; Aarons L
    Eur J Pain; 2013 Mar; 17(3):382-93. PubMed ID: 22893563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
    Wymer JP; Simpson J; Sen D; Bongardt S;
    Clin J Pain; 2009 Jun; 25(5):376-85. PubMed ID: 19454870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials.
    Othman AA; Nothaft W; Awni WM; Dutta S
    J Clin Pharmacol; 2012 Jul; 52(7):1028-41. PubMed ID: 21566201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects.
    Karyekar CS; Pradhan RS; Freeney T; Ji Q; Edeki T; Chiu W; Awni WM; Locke C; Schwartz LB; Granneman RG; O'Dea R
    J Clin Pharmacol; 2005 Aug; 45(8):910-8. PubMed ID: 16027401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
    J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Mittapalli RK; Nuthalapati S; Shepherd SP; Xiong H
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):587-594. PubMed ID: 28247011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
    Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
    Fukuhara K; Ikawa K; Morikawa N; Kumagai K
    J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cystatin C is a better marker of topotecan clearance than serum creatinine.
    Hoppe A; Séronie-Vivien S; Thomas F; Delord JP; Malard L; Canal P; Chatelut E
    Clin Cancer Res; 2005 Apr; 11(8):3038-44. PubMed ID: 15837759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain.
    Rowbotham MC; Arslanian A; Nothaft W; Duan RW; Best AE; Pritchett Y; Zhou Q; Stacey BR
    Pain; 2012 Apr; 153(4):862-868. PubMed ID: 22386472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain.
    Lee CH; Zhu C; Malysz J; Campbell T; Shaughnessy T; Honore P; Polakowski J; Gopalakrishnan M
    Biochem Pharmacol; 2011 Oct; 82(8):959-66. PubMed ID: 21763685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
    Mould D; Chapelsky M; Aluri J; Swagzdis J; Samuels R; Granett J
    Clin Pharmacol Ther; 2001 Apr; 69(4):210-22. PubMed ID: 11309549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.